- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01435590
Endocervical Evaluation With the Curette Versus Cytobrush for the Diagnosis of Dysplasia of the Uterine Cervix
May 27, 2015 updated by: Manuela Undurraga Malinverno, University Hospital, Geneva
OBJECTIVE: to compare endocervical brushing with endocervical curettage with respect to diagnostic and patient discomfort.
METHOD: women referred to colposcopy because of abnormal Papanicolaou tests will be randomized to endocervical sampling with either a metal curette (endocervical curettage -ECC) or and endocervical brush. All samples will be submitted for histological study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
180
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- French-speaking
- 21 years or older
- Attending our colposcopy clinic
- Need for endocervical evaluation
- Full autonomy or capacity to understand the procedures
Exclusion Criteria:
- Pregnancy
- Absence of uterus
- History of DES exposure in utero
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Specimen adequacy
Time Frame: 09/2011 - 05/2012 (1 year)
|
Cytological and histological interpretation of the endocervical brush specimens will then be performed, while for the endocervical currete specimens only histological interpretation will be done.
The adequacy of the specimens will be based on the quantity of endocervical cells present (< or ≥ 20 endocervical cells), the quantity of histological material (< or ≥ 3 epithelial stripes) and the quality of histological material (absence or presence of lamina propia).
|
09/2011 - 05/2012 (1 year)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient discomfort
Time Frame: 09/2011 to 05/2012 (8 months)
|
To evaluate the degree of patient discomfort, patients will be requested to complete a questionnaire once the exam has been completed.
The main acceptance variables will be degree of helplessness, pain (on visual analog scales), willingness to undergo the test again, and overall satisfaction.
Once the exam has been completed, the doctor performing the sampling will answer a questionnaire indicating his/her perception of the exam (patient's pain, technical difficulty performing the exam, doctors acceptability of the exam).
|
09/2011 to 05/2012 (8 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Actual)
September 1, 2014
Study Completion (Actual)
September 1, 2014
Study Registration Dates
First Submitted
September 13, 2011
First Submitted That Met QC Criteria
September 15, 2011
First Posted (Estimate)
September 16, 2011
Study Record Updates
Last Update Posted (Estimate)
May 28, 2015
Last Update Submitted That Met QC Criteria
May 27, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CER 11-029
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Dysplasia
-
University of Mississippi Medical CenterNot yet recruitingCervical Dysplasia, Uterine | Vaginal Dysplasia | Vulvar Dysplasia
-
National Institute of Allergy and Infectious Diseases...Hoffmann-La RocheCompletedHIV Infections | Cervix, DysplasiaUnited States, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Terminated
-
Sunnybrook Health Sciences CentreCompleted
-
Ruhr University of BochumCompletedUterine Cervical DysplasiaGermany
-
NHS Greater Glasgow and ClydeUnknownCervical Carcinoma | Cervical Dysplasia
-
University of CopenhagenDanish Cancer SocietyUnknown
-
University of TennesseeIntegra LifeSciences CorporationCompletedCervical DysplasiaUnited States
-
William Marsh Rice UniversityM.D. Anderson Cancer Center; Albert Einstein College of Medicine; The Cleveland... and other collaboratorsCompleted
-
Zydolab - Institute of Cytology and Immune CytochemistryCompleted
Clinical Trials on Curette v/s endocervical brush
-
The Institute of Molecular and Translational Medicine...National Institute for Cancer Research, Czech RepublicRecruitingCervical Cancer | Human Papillomavirus Infection | Cervical DysplasiaCzechia
-
Milton S. Hershey Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Postgraduate Institute of Dental Sciences RohtakRecruiting
-
Karaganda Medical UniversityMcMaster UniversityCompletedCovid19 | Vaccine Adverse ReactionKazakhstan
-
R-PharmAstraZeneca; Russian Direct Investment Fund; The Gamaleya National Center of...Completed
-
ImmunityBio, Inc.TerminatedCOVID-19United States
-
Hacettepe UniversityRecruiting
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Regina Elena Cancer InstituteIcahn School of Medicine at Mount Sinai; University of Roma La SapienzaUnknownMultiple Sclerosis | RelapseUnited States, Italy
-
National Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate CancerUnited States